Provided by Tiger Fintech (Singapore) Pte. Ltd.

ABVC BioPharma, Inc.

1.77
-0.0800-4.32%
Post-market: 1.770.00000.00%18:00 EDT
Volume:284.84K
Turnover:513.66K
Market Cap:28.76M
PE:-7.89
High:1.85
Open:1.80
Low:1.74
Close:1.85
Loading ...

ABVC Biopharma Inc. Conducted Annual Shareholders Meeting

Reuters
·
05 Jun

YUKIGUNI FACTORY Completes Share Buyback

TIPRANKS
·
30 May

ABVC BioPharma Files $100 Million Mixed Shelf

MT Newswires Live
·
23 May

BRIEF-Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing

Reuters
·
23 May

ABVC BioPharma files $100M mixed securities shelf

TIPRANKS
·
23 May

ABVC Biopharma Inc Files for Mixed Shelf of up to $100 Mln - SEC Filing

THOMSON REUTERS
·
23 May

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD

GlobeNewswire
·
20 May

Press Release: Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Dow Jones
·
15 May

Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years

Motley Fool
·
12 May

YUKIGUNI FACTORY Reports Impairment Loss Amid Production Challenges

TIPRANKS
·
09 May

YUKIGUNI FACTORY CO., LTD. Announces Share Buyback Plan

TIPRANKS
·
09 May

YUKIGUNI FACTORY Reports Financial Variances and Increased Dividends

TIPRANKS
·
09 May

Yukiguni Maitake Sees FY Net Y2.01B

Dow Jones
·
09 May

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
06 May

ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan

NewMediaWire
·
01 May

Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301

TIPRANKS
·
30 Apr

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

GlobeNewswire
·
29 Apr

UPDATE: ABVC BioPharma Announces 2024 Financial Results

NewMediaWire
·
16 Apr

ABVC BioPharma Determined That It Has A Material Weakness In Its Internal Controls Over Financial Reporting; Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements

Benzinga
·
16 Apr

ABVC Biopharma Inc: Determined That It Has a Material Weakness in Its Internal Controls Over Financial Reporting

THOMSON REUTERS
·
16 Apr